This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Cardiac dysrhythmias
  • /
  • An Update on Anticoagulation in Atrial Fibrillatio...
Journal

An Update on Anticoagulation in Atrial Fibrillation.

Read time: 1 mins
Published:31st Aug 2017
Author: Amerena J, Ridley D.
Availability: Pay for access, or by subscription
Ref.:Heart Lung Circ. 2017;26(9):911-917.
DOI:10.1016/j.hlc.2017.05.131

Cerebrovascular accidents related to atrial fibrillation (AF) are potentially preventable with anticoagulation. Until recently, warfarin was the only proven anticoagulant to be effective in stroke prevention, however the novel, direct acting oral anticoagulants (DOACs) are now available, triggering a paradigm shift in treatment philosophy. Today, physicians need to consider in which patients anticoagulation should not be used rather than, as in the past, deciding in which patients it should be used. Although warfarin will continue to have a place in managing some patients with AF, in the future, the DOACs should be the predominant therapy for stroke prevention in patients with non-valvular AF.

 

Read abstract on library site

Access full article